Dysregulation of SMAD4, LINC00667 and LINC00909 could be used as effective diagnostic markers in breast cancer incidence

Abstract

Abstract Breast cancer is considered a life-threatening disease among females globally which early diagnosis and treatment in the initial stages can be very effective. SMAD4 is a key regulator of TGF-β pathway that is known to play an essential role in breast cancer. Long non-coding RNAs (lncRNAs) are considered to be potential regulatory factors for several cancers that are not definite about the main role of two LncRNAs, LINC00909 and LINC00667, on breast cancer. In this study, we focus on identifying the possible correlation between expression levels of SMAD4 gene, LINC00909 and LINC00667 in breast carcinoma, as well as their potential roles in the diagnosis of breast cancer. To determine the extent of expression of these factors in 25 paired tumor-normal patient tissues, quantitative real-time PCR (polymerase chain reaction) was used. Statistical analysis showed a significant increase in the expression of the SMAD4 gene in tumor cells compared with control samples, while the expressions of LINC00909 and LINC00667 increased dramatically. As well as, specificity and sensitivity between all three criteria and breast carcinoma were statistically significant. furthermore, we observed the positive relationship between expression of LINC00909 and HER2/neu in the tumor tissues, whereas there was not another correlation between clinicopathological features and SMAD4 gene, LINC00909 and LINC00667. Moreover, we discovered a positive association between the expression of LINC00667 and LINC00909. altogether, we conclude that, SMAD4 could be considered as a potential diagnostic biomarker for breast cancer, and two lncRNAs, especially LINC00909, were identified to play an important role in the identification of breast cancer.